Table 2.
The presence of human bocaviruses 1-4 (HBoV1–4) and parvovirus B19 (B19V) genomic sequences among patients and control group.
| DNA Biological Material | Patients (n = 42) | Control Group (n = 50) |
|---|---|---|
| HBoV1–4 Positivity (n) | ||
| Blood b | 9 | 12 |
| Plasma a | 3 | 2 |
| CSF a | 2 | N/A |
| Blood + plasma a | 3 | 0 |
| Blood + CSF a | 3 | N/A |
| Blood + plasma + CSF a | 2 | N/A |
| Total | 22 | 14 |
| B19V Positivity (n) | ||
| Blood b | 4 | 2 |
| Plasma a | 1 | 1 |
| CSF a | 1 | N/A |
| Blood + CSF a | 1 | N/A |
| Total | 7 | 3 |
n—number of cases; DNA—deoxyribonucleic acid; HBoV1–4—human bocavirus 1 to 4; B19V—human parvovirus B19; CSF—cerebrospinal fluid; N/A—not applicable; a—active viral infection; b—persistent viral infection.